采用大隐静脉间置移植物的远端流入道翻修术治疗高流量肱动脉动静脉瘘的三年通畅率与复发率
该回顾性队列研究纳入2011年3月至2017年10月在三家机构接受大隐静脉间置移植的远端流入道翻修术(RUDI)的高流量肱动脉动静脉瘘患者21例,其中7例合并透析通路诱导的远端缺血(HAIDI)。术后流量下降三倍,3年总体一期通畅率48%±12,高流量复发与术后即刻高流量及年轻年龄相关。
要点
- 术后即刻流量从3120 mL/min±171降至1170 mL/min±87(p<.001)。
- 3年总体一期通畅率48%±12,HFA组55%±15 vs HAIDI/HFA组29%±17(p=.042)。
- 3年后51%±12患者免于高流量,HFA组32%±13 vs HAIDI/HFA组100%(p=.018)。
核心结论
- 采用大隐静脉间置移植的RUDI治疗高流量肱动脉动静脉瘘在3年后提供可接受的通畅率,尽管常需再次干预。
- 术后即刻高流量和年轻年龄与高流量复发相关。
研究设计与样本
- 回顾性队列研究,纳入2011年3月至2017年10月在三家机构接受大隐静脉间置移植RUDI的高流量肱动脉动静脉瘘患者21例(女性7例,年龄54岁±3)。
- 高流量定义为连续两次稀释法测量流量超过2 L/min;HAIDI按推荐标准诊断;术后随访与动静脉瘘患者标准照护无差异。
主要发现
- 术后即刻流量下降三倍(3120 mL/min±171 vs 1170 mL/min±87,p<.001)。
- 3年总体一期通畅率48%±12(HFA组55%±15 vs HAIDI/HFA组29%±17,p=.042)。
- 两组二期通畅率相同(总体84%±9)。
- 3年后51%±12患者免于高流量(HFA组32%±13 vs HAIDI/HFA组100%,p=.018)。
- 术后即刻高流量预测复发(OR 1.004 [1.000-1.007],p=.044);复发患者较无复发患者年轻12岁(p=.055)。
关键数值与推荐
- 高流量定义:连续两次稀释法测量流量超过2 L/min。
- 干预措施包括经皮腔内血管成形术(n=12,9例患者)、血栓切除术(n=7,3例患者)和置入新间置移植物的翻修术(n=3)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Upper arm arteriovenous fistulas (AVF) occasionally develop high flow. Revision using distal inflow (RUDI) effectively reduces flow of high flow accesses (HFA) in the short-term and is also popularised for treatment of haemodialysis access induced distal ischaemia (HAIDI). The long-term efficacy is unknown. The study's aim was to report on 3 year RUDI patency and recurrence rates for HFA with and without HAIDI. MATERIAL AND METHODS: This was a retrospective cohort study of patients with a HFA with or without HAIDI undergoing RUDI using greater saphenous vein (GSV) interposition between March 2011 and October 2017 at three facilities. AVFs were termed HFA if flow volumes exceeded 2 L/min on two consecutive measurements using dilution techniques. HAIDI was diagnosed as recommended. Following RUDI, follow up was not different from standard care in AVF patients. Data on post-operative flows and re-interventions were extracted from electronic patient files. Loss to follow up was avoided. Rates of patency and HFA recurrence were analysed. RESULTS: During the observation period, 21 patients were studied (7 females, 54 years ± 3). Fourteen had uncomplicated HFA whereas seven had additional HAIDI. Immediately post-operatively, flows decreased threefold (3120 mL/min ± 171 vs. 1170 mL/min ± 87, p < .001). Overall 3 year primary patency was 48% ± 12 (HFA, 55% ± 15 vs. HAIDI/HFA, 29% ± 17, p = .042). Secondary patency was identical in both groups (overall, 84% ± 9). Interventions were percutaneous transluminal angioplasty (n = 12, 9 patients), thrombectomy (n = 7, 3 patients), and revision with new interposition grafts (n = 3). After 3 years, 51% ± 12 were free of high flow (HFA, 32% ± 13 vs. HAIDI/HFA, 100%, p = .018). High immediate post-operative access flow predicted recurrence (OR 1.004 [1.000-1.007], p = .044). Patients with recurrence were 12 years younger than those without (p = .055). CONCLUSION: RUDI with GSV interposition for HFA offers acceptable patency rates after 3 years although re-interventions are often required. High immediate post-operative flows and young age are associated with recurrent high flow.
引用
- Gerrickens MWM, Vaes RHD, Govaert B, et al. Three Year Patency and Recurrence Rates of Revision Using Distal Inflow with a Venous Interposition Graft for High Flow Brachial Artery Based Arteriovenous Fistula. Eur J Vasc Endovasc Surg. 2018. PMID: 29680175. doi:10.1016/j.ejvs.2018.03.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。